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Summary
Background International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer (EOC) has a 
signifi cantly better prognosis than stage III/IV EOC, with about 80% of patients surviving at 5 years (compared with 
about 20% of those with stage III/IV EOC). However, 20% of patients with stage I EOC relapse within 5 years. It is 
therefore crucial that the biological properties of stage I EOCs are further elucidated. MicroRNAs (miRNAs) have 
shown diagnostic and prognostic potential in stage III and IV EOCs, but the small number of patients diagnosed with 
stage I EOC has so far prevented an investigation of its molecular features. We profi led miRNA expression in 
stage I EOC tumours to assess whether there is a miRNA signature associated with overall and progression-free 
survival (PFS) in stage I EOC.
Methods We analysed tumour samples from 144 patients (29 of whom relapsed) with stage I EOC gathered from two 
independent tumour tissue collections (A and B), both with a median follow-up of 9 years. 89 samples from tumour 
tissue collection A were stratifi ed into a training set (51 samples, 15 of which were from patients who relapsed) for 
miRNA signature generation, and into a validation set (38 samples, seven of which were from patients who relapsed) 
for signature validation. Tumour tissue collection B (55 samples, seven of which were from patients who relapsed) was 
used as an independent test set. The Cox proportional hazards model and the log-rank test were used to assess the 
correlation of quantitative reverse transcription PCR (qRT-PCR)-validated miRNAs with overall survival and PFS.
Findings A signature of 34 miRNAs associated with survival was generated by microarray analysis in the training set. 
In both the training set and validation set, qRT-PCR analysis confi rmed that 11 miRNAs (miR-214, miR-199a-3p, 
miR-199a-5p, miR-145, miR-200b, miR-30a, miR-30a*, miR-30d, miR-200c, miR-20a, and miR-143) were expressed 
diff erently in relapsers compared with non-relapsers. Three of these miRNAs (miR-200c, miR-199a-3p, miR-199a-5p) 
were associated with PFS, overall survival, or both in multivariate analysis. qRT-PCR analysis in the test set confi rmed 
the downregulation of miR-200c in relapsers compared with non-relapsers, but not the upregulation of miR-199a-3p 
and miR-199a-5p. Multivariate analysis confi rmed that downregulation of miR-200c in the test set was associated with 
overall survival (HR 0·094, 95% CI 0·012–0·766, p=0·0272) and PFS (0·035, 0·004–0·311; p=0·0026), independent 
of clinical covariates.
Interpretation miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC.
Funding Nerina and Mario Mattioli Foundation, Cariplo Foundation (Grant Number 2010-0744), and the Italian 
Association for Cancer Research.
Introduction
The 5-year survival of patients with epithelial ovarian 
cancer (EOC) depends on the spread of the disease at 
diagnosis. In patients with disease limited to the ovary 
(International Federation of Gynecology and Obstetrics 
[FIGO] stage I), survival is close to 80%. However, in 
cases in which the disease involves the upper abdomen 
or beyond (FIGO stages III and IV), only about 20% of 
patients survive at 5 years.1 Fewer than 20% of patients 
with stage I EOC have aggressive disease and relapse 
within 5 years of primary surgery, but an unresolved 
clinical issue is how to discriminate at an early stage 
between patients with curable stage I disease and those 
who will relapse after adjuvant chemotherapy. Prediction 
of relapse on the basis of currently known clinical and 
pathological features is diffi  cult.1 Predicting relapse 
might be possible with a better knowledge of the 
molecular and genetic mechanisms that are associated 
with each tumour stage. Knowledge of the molecular 
pathways that are altered during neoplastic transformation 
might help expedite the discovery of biomarkers for early 
disease detection, prediction of clinical response, and 
guidance of treatment.
Fewer than 10% of all patients with EOC diagnosed 
every year have stage I disease, which makes it diffi  cult to 
recruit patient cohorts of a size adequate to produce 
statistical power. Knowledge of the biological diff erences 
between stage I disease, which is curable in most cases, 
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and stage III, which is generally incurable, is limited, 
although important biological diff erences between stage I 
and stage III disease have been suggested. All patients 
with stage I disease express wild-type P53, whereas a 
large proportion of patients with stage III disease have 
mutated P532 or abnormal levels of other members of the 
P53 family (eg, increased expression of DNp63).3 In a 
collection of tumour  samples from a cohort of 68 stage I 
tumours and 15 tumours with low malignant potential 
(also known as borderline) selected from a collection of 
fresh-frozen samples available at the Mario Negri 
Institute, we recently defi ned a gene-expression signature 
that distinguished patients with stage I disease who 
relapsed from those who did not.4
MicroRNAs (miRNAs) are small 21–23 nucleotide long 
non-coding RNAs.5 During the past 5 years the importance 
of miRNAs in cell biology has been confi rmed, and the 
case for their role in disease, particularly cancer, is 
compelling. The use of array technologies to characterise 
miRNAs in cancer tissue banks has discovered unique 
miRNA-expression patterns related to clinical features of 
several cancers. The present hypothesis is that miRNAs 
can be used to generate discriminators with diagnostic 
and prognostic value in situations where histology and 
mRNA-based diagnostic tools are defi cient.
Studies of stage III and IV EOC and of ovarian cancer 
cell lines suggest that miRNAs are downregulated in 
tumour samples compared with normal tissue, and that 
their altered expression aff ects response to chemotherapy. 
Genes involved in the biogenesis of miRNAs were also 
altered in EOC. Dicer and Drosha mRNA and protein 
concentrations have been associated with outcome in a 
cohort of 108 stage III and stage IV ovarian tumours.6 
There appear to be no published studies on stage I 
ovarian cancers, perhaps because of the relatively small 
proportion of patients who present with stage I disease. 
We aimed to investigate the association between miRNAs 
and prognosis in stage I EOC. To that end, we studied a 
genome-wide miRNA-expression profi le in tumour 
samples from a cohort of 144 patients (29 of whom 
relapsed) with stage I EOC.
Methods
Sample collection
Tumour samples from a cohort of 144 patients 
staged according to the FIGO criteria as stage I EOC7 were 
gathered from two independent tumour tissue collections 
(collections A and B). For collection A, 89 samples were 
taken from a frozen tissue bank containing 1300 samples 
that were collected between September, 1992, and 
March, 2005, and available at the Department of Oncology, 
Mario Negri Institute, Milan, Italy. Tumour tissue had been 
collected from patients who underwent surgery for EOC at 
the Obstetrics and Gynecology Department, San Gerardo 
Hospital, Monza, Italy, as described previously.4 For 
collection B, 55 samples were taken from the collection of 
600 frozen samples that were collected between 
January, 1992, and December, 2005, and available at the 
Department of Gynecology-Oncology, University of Torino, 
Torino, Italy. The study was done on samples from patients 
with stage I EOC and at least 5 years follow-up data. 
Samples had been collected in the operating theatre from 
patients undergoing cytoreductive surgery, frozen within 
15 min in liquid nitrogen and stored at –80°C.
The tumour content of the specimens in collections A 
and B was assessed by haematoxylin and eosin stain in 
the pathology units. Only specimens containing more 
than 70% of tumour tissue were used. Patients’ clinical 
and anatomo-pathological information was registered, 
and follow-up data was obtained from periodic 
gynecological oncological check-ups. The collection and 
use of tumour samples was approved by the local 
scientifi c ethical committees and written consent was 
obtained from the patients. 
Samples from collection A were randomly allocated 
with a ratio of 4:3, stratifi ed by substage and grade, into a 
training set and a validation set. Samples from collection B 
were defi ned as the test set.
Tissue collection A Tissue collection B
Overall
(n=89)
Training set
(n=51)
Validation set
(n=38)
Test set
(n=55)
Median age (range) years 52 (21–82) 51 (23–82) 55 (21–75) 57 (48–69)
Chemotherapy
Yes 61 (69%) 38 (75%) 23 (61%) 33 (60%)
No 28 (31%) 13 (25%) 15 (39%) 22 (40%)
Histotype*
Clear cell 14 (16·1%) 8 (16·00%) 6 (16·22%) 6 (11%)
Endometroid 23 (26·4%) 15 (30·00%) 8 (21·62%) 19 (35%)
Mucinous 20 (22·99%) 14 (28·00%) 6 (16·22%) 9 (16%)
Mullerian 0 (0·00%) 0 (0·00%) 0 (0·00%) 2 (4%)
Serous 29 (33·33%) 12 (24·00%) 17 (45·95%) 13 (24%)
Undiff erentiated 1 (1·15%) 1 (2·00%) 0 (0·00%) 6 (11%)
Figo I substage
A 28 (31%) 17 (33%) 11 (29%) 22 (40%)
B 5 (6%) 3 (6%) 2 (5%) 8 (15%)
C 56 (63%) 31 (61%) 25 (66%) 25 (45%)
Grade
1 23 (26%) 13 (25%) 10 (26%) 23 (42%)
2 28 (31%) 15 (29%) 13 (34%) 10 (18%)
3 38 (43%) 23 (45%) 15 (39%) 22 (40%)
Figo I substage (chemotherapy)
A 13 (21%) 9 (24%) 4 (17%) 8 (24%)
B 5 (8%) 3 (8%) 2 (9%) 5 (15%)
C 43 (70%) 26 (68%) 17 (74%) 20 (61%)
Figo I substage (no chemotherapy)
A 15 (54%) 8 (62%) 7 (47%) 14 (64%)
B 0 (0%) 0 (0%) 0 (0%) 3 (14%)
C 13 (46%) 5 (38%) 8 (53%) 5 (23%)
All data are n (%) unless stated otherwise. *There was one missing value each in the training and validation set.
Table 1: Main characteristics of patients and tissue samples
Articles
www.thelancet.com/oncology   Vol 12   March 2011 275
Procedures
Frozen samples (30 mg) were homogenised in an 
Ultraturrax at 4°C, and total RNA enriched in miRNAs 
fraction was purifi ed using a mirVana isolation kit 
according to the manufacturer’s instructions (Ambion-
ABI, Milan, Italy). RNA was measured by Nanodrop, and 
the presence of small RNAs was checked with a 
2100 Bioanalyser (Agilent Technologies, Santa Clara, CA, 
USA). Aliquots were stored at –80°C until use. 100 ng of 
total RNA enriched in miRNA fraction was Cy5-labelled 
and hybridised with a miRNA labelling and hybridisation 
kit according to the manufacturer’s instructions (Agilent 
Technologies). We used the commercially available 
G4470B human miRNA Microarray kit (Agilent 
Technologies), which consists of 15K features printed in 
an 8-plex format (8×15 array), and can detect all known 
human miRNAs (723 human and 76 human-viral 
miRNAs) sourced from the Sanger miRBASE public 
database, release 10.1. The arrays were washed and 
scanned with a laser confocal scanner (G2565BA, Agilent 
Technologies) according to the manufacturer’s 
instructions. miRNA microarrays underwent standard 
post hybridisation processing and the intensities of 
fl uorescence were calculated by Feature Extraction 
software version 11 (Agilent Technologies).
Analysis of microarray data
Raw data were pre-processed to fi lter out those probes 
with more than 40% of measurements classed as not 
available. The fi lter on the coverage of the probes was done 
to reduce biases in the normalisation step. Pre-processed 
data were normalised using cyclic lowess.8 To identify 
miRNAs that were expressed diff erently in relapsers 
compared with non-relapsers, we did a two-class unpaired 
signifi cance analysis of microarrays (SAM) test,9 with 
100 random permutations of the results. p values and their 
corresponding q values (the adjusted p value for false 
discovery rate; FDR) were used to control test multiplicity, 
with 25% chosen the cutoff . q values for each miRNA 
were defi ned as q=(p*n)/i, where p is the raw p value of 
the gene, n the total number of genes, and i is the number 
of genes at or better than p. Statistical analyses were done 
using the R programming language (version 2.11), and the 
Bioconductor software suite (version 2.6). Microarray raw 
data have been submitted to ArrayExpress (experiment 
number E-MTAB-297), in accordance with MIAME 
(minimum information about a microarray experiment) 
guidelines. Clustering analysis was done on normalised 
data. Single miRNA signals for each patient were divided 
by a baseline signal defi ned as the mean of the signal of 
that specifi c miRNA in all patients. A subset of the 
previously mentioned matrix was made using only 
34 miRNAs coming from the analysis of diff erential 
expression. Hierarchical dendrograms were calculated 
with Pearson’s correlation as clustering metric and by 
bootstrapping data over 1000 iterations. The calculation 
was done with the TIGR Multi-experiment Viewer feature 
of the TM4 software suite (version 4.4).10
Overall survival Progression-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age (5-year increment) 1·324 (1·051–1·670) 0·0175 1·236 (0·939–1·628) 0·1309 1·225 (1·028–1·459) 0·0231 1·249 (1·011–1·543) 0·0394
Chemotherapy (yes vs no) 8·230 (1·085–62·435) 0·0415 3·230 (0·367–28·448) 0·2909 14·543 (1·955–108·184) 0·0089 11·226 (1·376–91·560) 0·0239
Histotype
Clear cell (reference) .. .. .. .. .. .. .. ..
Endometroid 0·152 (0·03–0·754) 0·0212 0·328 (0·036–3·001) 0·3240 0·321 (0·095–1·086) 0·0676 0·619 (0·112–3·417) 0·5825
Undiff erentiated 1·983 (0·235–16·718) 0·5291 1·532 (0·177–13·246) 0·6981 4·391 (0·503–38·373) 0·1810 3·791 (0·427–33·628) 0·2314
Mucinous 0·170 (0·034–0·846) 0·0305 1·563 (0·163–14·958) 0·6983 0·134 (0·026–0·701) 0·0173 0·973 (0·141–6·741) 0·9782
Serous 0·285 (0·086–0·941) 0·0394 0·777 (0·189–3·202) 0·7271 0·650 (0·236–1·791) 0·4043 2·698 (0·838–8·679) 0·0960
Figo I substage
A (reference) .. .. .. .. .. .. .. ..
B 6·014 (0·376–96·265) 0·2048 3·093 (0·141–67·908) 0·4737 3·692 (0·326–41·832) 0·2917 0·750 (0·060–9·352) 0·8234
C 7·951 (1·045–60·491) 0·0452 5·659 (0·638–50·187) 0·1196 7·513 (1·709–33·025) 0·0076 4·715 (1·028–21·627) 0·0460
Grade
1 (reference) .. .. .. .. .. .. .. ..
2 3·415 (0·382–30·568) 0·2720 2·987 (0·262–34·126) 0·3785 1·760 (0·438–7·068) 0·4253 1·172 (0·222–6·179) 0·8517
3 7·652 (0·987–59·308) 0·0514 3·546 (0·309–40·663) 0·3092 3·674 (1·063–12·699) 0·0398 1·251 (0·292–5·365) 0·7633
Cluster All (2 vs 1) 0·798 (0·240–2·651) 0·7122 0·569 (0·088–3·662) 0·5526 0·770 (0·273–2·177) 0·6224 0·285 (0·039–2·069) 0·2148
Cluster DEG (2 vs 1) 3·894 (0·852–17·786) 0·0795 4·207 (0·417–42·476) 0·2233 3·744 (1·065–13·163) 0·0396 5·499 (0·618–48·930) 0·1264
Cox proportional hazards regression analysis of overall and progression-free survival for the 89 patients with stage I EOC from tumour tissue collection A. Cluster analyses performed only on the 51 patients of 
the training set.
Table 2: Univariate and multivariate analysis of tumour tissue collection A
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miRNA real-time RT-PCR
Mature miRNA expression levels were examined by 
real-time reverse transcription PCR (RT-PCR) using 
dedicated sets of commercial primers (Qiagen, Milan, 
Italy). Briefl y, specifi c cDNA was generated in a single-
step reaction from 1 μg of mirVana-purifi ed total RNA 
(Ambion-ABI, Milan, Italy), using the the miScript 
Reverse Transcription Kit, following the manufacturer’s 
instructions. miRNA expression was quantifi ed by Sybr 
Green chemistry using the commercial miScript 
Universal Primer, together with the miScript Primer 
Assay (Qiagen). Experiments were run in triplicate for 
each case to allow for technical variability, using 
384-well reaction plates in an automatic liquid handling 
station (epMotion 5075LH; Eppendorf, Milan, Italy). 
Real-time PCR was done on an Applied Biosystems 
7900HT (Ambion-ABI). Raw data was generated with 
SDS Relative Quantifi cation software (version 2.3; 
Ambion-ABI) and analysed using the R software 
package (version 2.11), as described3 using RU-6b as a 
housekeeping gene. For miRNA expression 
experiments, median values were compared using the 
non parametric Mann-Whitney t test. Diff erences were 
considered statistically signifi cant with a two sided 
p-value of less than 0·05. All tests and data plots were 
done using GraphPad Prism (version 5.01).
qRT-PCR
Quantitative reverse transcription real-time-PCR (qRT-
PCR) was used to validate the diff erential expression of 
selected genes in EOC biopsies. The automatic liquid-
handling station (epMotion 5075LH; Eppendorf), 
real-time PCR (ABI-7900; Applied Biosystems), and 
primer pairs sequences for the four housekeeping genes 
used for data normalisation (actin, 28S, GAPDH, and 
cyclophilin A) were as previously described.3 Primer 
pair sequences for VEGFA (NM_001171630): 
Fw, GGAGGAGGGCAGAATCATCA and Rv, 
TCCGCATAATCTGCATGGTG; for TUBB3 
(NM_006086): Fw, CGAAGCCAGCAGTGTCTAAA and 
Rv, GGAGGACGAGGCCATAAATA; for DICER 
(NM_177438): Fw, CGTGCTGCAGTAAGCTGTG and Rv, 
TCTTCCCTGAGCCAGTGTTT; for DROSHA 
(NM_013235): Fw, AGATCTGGAAGGAGTTACGGTTT 
and Rv, GGTTGTCACTCCAACGGTCT. For ZEB1 
(NM_030751): Fw, CGGCGCAATAACGTTACAA and Rv, 
CATCCTCTGGTACACCTTCACA; for TGFBR2 
(NM_003242): Fw, GGGGAAACAATACTGGCTGA and 
Rv, GAGCTCTTGAGGTCCCTGTG. The annealing 
temperature was 60°C. Absolute copy numbers were 
determined by qRT-PCR with the Sybr Green protocol, as 
previously described.3 For gene-expression experiments, 
medians were compared using the non-parametric 
Figure 1: Developing a prognostic miRNA signature in stage I EOC
A subset of 51 samples from tumour tissue collection A (89 samples of stage I EOC; training set) was used to develop a prognostic micro RNA (miRNA) signature. 
Microarray analysis identifi ed 18 miRNAs as being diff erentially expressed in tumour samples from patients who relapsed versus samples from non-relapsing 
patients. These data were validated by qRT-PCR (survival signature 1, S1) in the training set. In an independent subset made up of the remaining samples from 
collection A (validation set; n=38), 11 out of 18 miRNAs were confi rmed as being diff erentially expressed in samples from patients who relapsed versus samples from 
non-relapsing patients (survival signature 2, S2). Of these, only three miRNAs correlated with overall survival (OS) or progression-free survival (PFS) in multivariate 
analysis (survival signature 3, S3), and therefore their expression was assessed in tumour tissue collection B (55 samples of stage I EOC; test set). Only miR-200c was 
diff erentially expressed in samples from patients who relapsed versus samples from non-relapsing patients, and correlated with overall survival and PFS.
Tumour tissue collection A Tumour tissue collection B
51 samples in the training set Samples from 89 patients with
stage I EOC
38 samples in the validation set
Signature(s) correlation with
overall and progression-free survival
S1: first validated 
miRNA
survival signature 
(18 markers)
S3: validated 
miRNA
survival signature 
(3 markers)
S2: second validated 
miRNA
survival signature 
(11 markers)
Samples from 55 patients with 
stage I EOC
miR-200c signature correlation with
overall and progression-free survival
Validation in test set
Survival signature
generation by
miRNA array
(34 markers) 
Survival signature
validation by
qRT-PCR
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Mann Whitney t test. Diff erences were considered 
statistically signifi cant with a two sided p-value less than 
0·05. All tests and data plots were done using GraphPad 
Prism (version 5.01).
miRNA target gene predictions
To assess possible biological mechanisms involving any 
identifi ed miRNAs, we used the results of a previously 
published study on gene-expression profi les (obtained from 
the same biological samples as for miRNAs expression 
profi les) in ovarian cancer.4 We expected that putative 
targets of identifi ed miRNAs would have been diff erentially 
expressed (under the assumption that miRNA alters targets 
expression). Thus, we fi rst identifi ed putative targets with 
TargetScan version 5.1,11 and then retained only those 
targets previously identifi ed as diff erentially expressed. The 
resulting genes were reported according to the length of 
the alignment (seven or eight base pairs) with the miRNA 
seed and its level of evolutionary conservation.12
Statistical analysis 
We assessed the association between clinical features 
and miRNA expression with overall survival and 
progression-free survival (PFS). Overall survival was 
defi ned as the time from the diagnosis to the date of death 
from any cause. Patients known to be alive at the time of 
analysis were censored at their last available contact date. 
PFS was defi ned as the time from the diagnosis to the fi rst 
appearance of relapse or progressive disease. Patients were 
monitored during follow-up with a physical examination, 
including pelvic examination, and serum CA-125 
measurement. In instances where there were abnormal 
fi ndings a CT scan was done, and relapse was defi ned 
according to RECIST (Response Evaluation Criteria In 
Solid Tumours)13 criteria or death from any cause; patients 
known to be alive and free of progressive disease at the 
time of analysis were censored at their last available follow-
up assessment. The Contal and O’Quigley method14 was 
applied (SAS macro was provided by Mandrekar and 
colleagues) to choose a cutoff  value for the expression of 
each miRNA and mRNA that best discriminates between 
patients with or without an event during follow-up. Patients 
were classifi ed according to their miRNA or mRNA 
expression as under or over the cutoff  points computed to 
discriminate for death (in overall survival) or for progression 
or death (in PFS). Survival curves were estimated using the 
Figure 2: Unsupervised two-dimensional hierarchical cluster analysis of all miRNAs (A) and the miRNA signatures (B)
Each row represents a single miRNA and each column a tumour. The colours of the legend bar indicate the size of gene-expression changes, green for values 
between 0 and 1, and red for those larger than 1 (numbers beside the bar). The colours of branches, as shown in the legend, represent the bootstrap support of the 
division in clusters. Bootstrapping is a measure indicating how well the resulting tree is supported by the source data. The black branches divide the set of patients 
into two clusters for each tree. In panel A, the patients between 4416 and 1730 make up the fi rst cluster, and those patients between 8429 and 6174 form the second 
cluster. In panel B, the two clusters are made up of patients from 1266 to 2632 and from 9714 to 6174.
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Kaplan-Meier method, and the results of the log-rank test 
were added. The Cox proportional hazards model was used 
to test demographic characteristics, clinical features, and 
miRNA or mRNA expression for their association with 
PFS and overall survival. The assumption of proportional 
hazards was verifi ed with Schoenfeld’s residuals. Hazard 
ratios (HR) with 95% CI were calculated for each factor. 
When no events occurred in a variable level, the Cox model 
fails to estimate HR. In this case, “not determined” is 
reported. In the multivariate model each miRNA (S2 and 
S3 signature) or mRNA (VEGFA and TUBB3) was inserted 
together with demographic characteristics and clinical 
features so as not to overlook the potential confounding 
role of all the available variables.
A likelihood test was done to assess whether the addition 
of each miRNA in the Cox proportional hazards 
multivariate model gave a better fi t than the multivariate 
model with only demographic characteristics and clinical 
features. The receiver-operating-characteristic (ROC) 
curve was plotted, and the non-parametric estimate of the 
area under the ROC curve, the C-statistic, was computed 
for each model. Because standard methods do not exist for 
deriving a ROC curve for time-to-event data, we used 
occurrence and non-occurrence of events within 10 years 
as the outcome of these analyses. Diff erences in the 
C-statistic were tested to compare the ability to classify 
risk of models with demographic characteristics, clinical 
features, and miRNA expression level versus models with 
only demographic characteristics and clinical features.15 
Statistical signifi cance was set at a p value of less than 0·05. 
Analysis was done using SAS software (version 9.1).
Role of the funding source
No sponsor was involved in the study design, data 
collection, data analysis, data interpretation, writing 
the report, or in the decision to submit for publication. 
The corresponding author had full access to all the data 
in the study, and had fi nal responsibility for the decision 
to submit for publication.
Results
Table 1 shows histopathology of the tumour samples and 
the number of patients who received post-surgical 
chemotherapy. Briefl y, for tumour tissue collection A, the 
median age at diagnosis was 52 years (IQR 21–82 years), 
and the median follow-up time was 9·2 years (IQR 
6·9–11·6 years), with 87·5% of patients surviving and 
78·5% of patients were progression free at 5 years. 
Platinum-based adjuvant chemotherapy was given to 61 of 
89 patients. For tumour collection B, the median age at 
diagnosis was 57 years (IQR 48–69 years), and the median 
follow-up time was 8·9 years (IQR 6·1–11·9 years), with 
92·2% of patients surviving and 86·1% of patients were 
progression free at 5 years. Platinum-based adjuvant 
chemotherapy was given to 33 of 55 patients. The slight 
diff erence in terms of PFS and overall survival between 
tumour tissue collections A and B (webappendix p 1) could 
be explained by the fact that collection A includes more 
patients with stage IC disease, which has a worse prognosis 
than stage IA and IB (table 1). PFS and overall survival 
were similar to those reported in the literature with respect 
to age, substage, grading, and histotype.1 None of the 
patients presented with any P53 mutation. 22 of 89 samples 
in tissue collection A and seven of 55 in tissue collection B 
came from patients who relapsed, and are referred to from 
this point onwards as relapsers. Univariate Cox 
proportional hazards model indicated that age, 
chemotherapy, and histotype were associated with both 
overall survival and PFS (table 2). Substage was only 
signifi cantly associated with PFS (table 2). In the 
multivariate model, no variable was signifi cantly associated 
with overall survival, whereas age, chemotherapy, and 
substage were signifi cantly associated with PFS (table 2).
To identify the entire repertoire of miRNAs in patients 
with stage I EOC, we did miRNA microarray experiments 
(fi gure 1). We profi led the training set (51 samples from 
tissue collection A, 15 of which were from patients who 
relapsed), and found 34 miRNAs that were expressed 
diff erently in relapsed and non-relapsed patients 
(webappendix p 2). To investigate similarity across 
qRT-PCR Array 
Non relapsers (n=36) Relapsers (n=15) R p Ra q (%) 
Upregulated miRNAs
miR-223 398·4 (142·8–1182) 1820 (617·9–3730) 4·56 0·0039 2·72 0
miR-125b 29·17 (22·26–63·97) 77·46 (29·83–197·3) 2·65 0·014 1·52 0
miR-200a 148·1 (88·57–211·2) 300·1 (170·4–898·4) 2·02 0·0005 1·70 0
miR-200b 74·90 (41·57–134·1) 217·8 (99·01–367) 2·9 0·014 1·57 0
miR-22 81·82 (59·03–312·1) 145·3 (89·69–250·4) 1·77 0·0023 1·36 0
miR-143 140·8 (47·87–116·3) 8323 (4493–24977) 101·7 <0·0001 1·93 0
miR-214 213·3 (109·8–344·2) 309·6 (221·7–593·5) 1·61 0·031 1·67 24·77
miR-199a-3p 147 (54·97–435·2) 381·2 (203·8–839·5) 2·59 0·012 1·64 24·77
miR-199a-5p 124·5 (60·42–343·8) 207·4 (162·9–476·3) 1·66 0·049 1·68 24·77
miR-145 20·59 (10·29–50·08) 32·05 (20·16–109·4) 1·55 0·024 1·73 24·77
miR-194 6161 (569·9–10574) 8323 (4493–24977) 1·35 0·037 12·12 24·77
let-7i 82·57 (40·51–131·9) 76·40 (48·29–150·9) 0·92 0·693 0·72 24·77
Downregulated miRNAs
miR-30a 190 (104–243·1) 75·96 (41·99–145·6) 0·39 0·0027 0·48 24·77
miR-30a* 674·3 (426–1709) 431·2 (253·5–715·4) 0·64 0·018 0·43 24·77
miR-30d 250·2 (184·2–385·9) 116 (75·31–263) 0·46 0·026 0·69 24·77
miR-92a 42·14 (14·77–61·57) 17·97 (7·06–38·70) 0·42 0·041 0·73 24·77
miR-141 501·6 (290·6–708·6) 271 (132·8–539·7) 0·54 0·029 0·72 24·77
miR-17 803·9 (416·8–1295) 526·6 (244·5–1283) 0·65 0·35 0·69 24·77
miR-200c 20·22 (10·79–32·80) 6·96 (5·72–17·26) 0·34 0·0071 0·74 24·77
miR-20a 6·81 (5·22–13·01) 4·29 (1·63–7·83) 0·62 0·019 0·72 24·77
miR-361-5p 3754 (1640–6514) 2920 (1090–4838) 0·77 0·25 0·68 24·77
Expression analysis was done in the training set in patients who relapsed compared with those who did not. All data are 
median distribution (IQR) of fl uorescence intensity, normalised, unless otherwise stated. R=the ratio of the median 
distribution of relapsers to non-relapsers measured by real-time qRT-PCR, as described in the Methods section. Ra=the 
ratio of relapsers to non-relapsers measured by array technology. p=the level of signifi cance according to the 
Mann-Whitney t test. q (%) is as defi ned in the Methods section.
Table 3: RT-PCR expression analysis of selected miRNA from the initial survival signature
See Online for webappendix
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samples, an unsupervised cluster analysis was done on 
expression values of all miRNAs (fi gure 2A) and on 
diff erentially expressed miRNAs (fi gure 2B). The absolute 
expression values of each miRNA in each patient were 
divided by the mean of expression of that specifi c miRNA 
in all patients. Bootstrap analysis then enabled us to 
quantify the robustness of the clustering. Using a 
resampling approach on diff erentially expressed genes, 
the similarity structure of the data was perturbed, and the 
support of the cluster is defi ned as the number of times 
the cluster occurs in the perturbed data. The cluster 
analysis enabled us to divide samples into two groups 
(characterised by 100% bootstrap support). These groups 
were further investigated with a Cox proportional hazards 
model to assess their association with overall survival and 
PFS (table 2). Univariate analysis of PFS suggests that the 
signature of 34 miRNAs reported in table 2 as cluster 
DEG (diff erentially expressed genes) enabled us to 
separate patients on the basis of prognosis: the two 
clusters reported as cluster 1 and 2 (fi gure 2B) had 
signifi cantly diff erent prognosis in terms of PFS (table 2). 
No other association with clinical parameters was 
detected. By contrast, cluster analysis of all miRNAs 
(fi gure 2A) did not discriminate between patients on the 
global scale (shown in table 2 as Cluster All), suggesting 
that only a small subset of miRNAs is responsible for 
diff erences between relapsers and non-relapsers. This 
hypothesis was strengthened by association analysis on 
the two clusters (fi gure 2B), where there was an indication 
that one or more miRNAs included in the list could 
potentially be markers of relapse.
To assess the reproducibility and robustness of the 
miRNA signature identifi ed in the training set, we 
measured by qRT-PCR the expression of all 34 miRNAs; 
however, only the six top ranking miRNAs (q=0) and 50% 
of the miRNAs with a q value less than 25% were 
analysable. Experiments were done on both the training 
and validation set of tumour collection A (fi gure 1). To 
correct for a potential batch eff ect, new batches of snap-
frozen material for the entire cohort of samples from 
tissue collection A were used. qRT-PCR results for the 
training set indicate the median distribution levels of 
normalised fl uorescence intensity and the IQR of 
upregulated or downregulated miRNAs in relapsers (n=15) 
compared with non-relapsers (n=36); Mann-Whitney t test 
confi rmed the diff erence in expression level between 
relapsers and non-relapsers for 18 of the 21 selected 
miRNAs (table 3). There were signifi cant diff erences in 
the expression levels of the top six ranked miRNAs 
between relapsers and non-relapsers. By contrast, miR-17, 
miR-361, and let-7i were not expressed diff erently in 
relapsers and non-relapsers, and were excluded from 
further analysis. The 18 miRNA with confi rmed diff erences 
in expression between relapsers and non-relapsers were 
thus selected for further analysis (S1 signature; fi gure 1). 
The Pearson correlation index between array and qRT-
PCR data was 0·898, suggesting substantial overlap. Box 
plots showing the distribution of expression levels of the 
21 selected miRNAs are shown (webappendix p3–4).
Table 4 shows qRT-PCR results from the validation set 
(31 samples from non-relapsing and seven samples from 
relapsed patients). Although the diff erences in the 
expression levels mirrored those reported in table 3, only 
11 miRNAs from the S1 signature were signifi cantly 
diff erently expressed between patients who relapsed and 
patients who did not. miR-214, miR-199a-3p, miR-199a-5p, 
miR-145, miR-200b, and miR-143 were confi rmed 
upregulated in tumour tissue samples from relapsers 
compared with non-relapsers. miR-30a, miR-30a*, 
miR-30d, miR-200c, and miR-20a were downregulated in 
samples from relapsers relative to non-relapsers (table 4). 
We defi ned this signature of 11 validated miRNAs as S2 
(fi gure 1).
We investigated the association of the S2 miRNAs with 
survival in collection A (table 5). In a univariate model, 
patients who expressed high levels of miR-199a-3p and 
miR-199a-5p had a signifi cantly lower overall survival 
and PFS than did patients with low expression levels 
(table 5). Figure 3 shows Kaplan-Meier curves by 
expression levels of miR-199a-3p and miR-199a-5p, 
confi rming these fi ndings. These associations were 
confi rmed in the multivariate model, where demographic 
characteristics and clinical features were taken into 
account: both miR-199a-3p and miR-199a-5p maintained 
their signifi cant association with PFS, but only 
miR-199a-3p was signifi cantly associated with overall 
Non-relapsers (n=31) Relapsers (n=7) R p 
Upregulated miRNAs
miR-223 699·1 (368–2029) 798·3 (165·7–3165) 1·44 0·73
miR-214 275·8 (127·4–401·7) 1105 (274–4610) 4 0·029
miR-199a-3p 157·4 (64·29–540·7) 593·9 (164·7–1519) 3·77 0·033
miR-199a-5p 252·3 (109·5–450·6) 1025 (574·8–1637) 4·06 0·0084
miR-145 39·38 (19·18–84·62) 130·4 (39·18–347·3) 3·31 0·031
miR-200b 50·65 (38·60–79·44) 120·5 (86·60–127·1) 2·37 0·024
miR-125b 51·67 (24·92–108·9) 68·40 (21·98–356) 1·02 0·66
miR-200a 162 (79·71–259) 149·7 (88·47–259·6) 0·92 0·8
miR-143 200·1 (118·7–313·9) 589·2 (245·3–922·1) 2·94 0·0148
miR-194 5935 (1262–10 601) 4973 (3670–9895) 0·83 0·985
Downregulated miRNAs
miR-30a 157·7 (82·83–225) 73·23 (53·89–97·84) 0·46 0·014
miR-30a* 896·5 (580·6–1211) 281·6 (197·1–577) 0·31 0·028
miR-30d 288·1 (197·9–376) 145·9 (87·72–185·2) 0·50 0·032
miR-92a 31·92 (22·28–49·95) 37·92 (8·76–51·44) 0·60 0·67
miR-141 370·9 (225·1–664·1) 226·3 (167·8–536) 0·61 0·17
miR-200c 14·95 (11·76–27·06) 7·47 (5·41–15·33) 0·49 0·019
miR-20a 10·97 (8·56–15·52) 6·94 (3·44–10·63) 0·63 0·043
miR-22 136·6 (73·49–211·5) 91·51 (72·23–137·5) 0·67 0·54
All data are median distribution (IQR) of fl uorescence intensity, normalised, unless otherwise stated. R=the ratio of the 
median distribution of relapsers compared with non-relapsers. p=the level of signifi cance according to the 
Mann-Whitney t test.
Table 4: RT-PCR expression analysis of the S2 signature in the validation set
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survival (table 5). The Cox proportional hazards model 
explained the survival data signifi cantly better with the 
inclusion of miR-199a-3p and miR-199a-5p than without 
these miRNAs, both in analysis of overall survival (for 
miR-199a-3p the likelihood ratio [LR] was 7·12, p=0·0076; 
and for miR-199a-5p LR was 5·74, p=0·0165) and PFS 
(for miR-199a-3p LR was 9·47, p=0·0021; for 
miR-199a-5p LR was 7·94, p=0·0048). Adding miR-199a-3p 
to the multivariate model improved the C-statistic 
by 5·80% (from 0·82, 95% CI 0·70–0·95, to 0·87, 
0·75–0·99) for overall survival and by 4·70% (from 0·83, 
0·73–0·92, to 0·87, 0·77–0·96) for PFS. Adding 
miR-199a-5p improved the C-statistic by 4·73% 
(from 0·82, 0·70–0·95, to 0·86, 0·74–0·98) for overall 
survival and by 3·67% (from 0·83, 0·73–0·92, to 0·86, 
0·76–0·95) for PFS. These improvements were not found 
to be statistically signifi cant.
The expression level of miR-200c was found to be 
signifi cantly associated with both overall survival and 
PFS in univariate analysis (table 5). Patients with high 
expression levels of miR-200c survived for longer than 
did those with low levels; similarly, patients with high 
expression levels of miR-200c had a longer PFS than did 
those with low levels (table 5). The Kaplan-Meier curves 
in fi gure 3 confi rm these results: patients with high 
expression levels of miR-200c had a better prognosis than 
those with low levels, both in terms of overall survival 
and PFS. A multivariate Cox proportional hazards model 
was fi tted to test the eff ect of expression level on survival, 
taking into account the eff ect of demographic 
characteristics and clinical features. miR-200c maintained 
its signifi cance as an independent prognostic factor for 
overall survival, but not for PFS (table 5). Including 
miR-200c signifi cantly improved the fi t of the Cox 
proportional hazards model in an analysis of overall 
survival (LR 5·79, p=0·0161), but not in an analysis of 
PFS (LR 2·57, p=0·1088). Adding miR-200c to the 
multivariate model improved the C-statistic by 2·79% 
(from 0·82, 95% CI 0·70–0·95, to 0·84, 0·72–0·97) for 
overall survival, and by 1·17% (from 0·83, 0·73–0·92, 
to 0·84, 0·74–0·93) for PFS. However, these 
improvements were not signifi cant.
RT-PCR was applied to miR-199a-3p, miR-199a-5p, 
and miR-200c (S3 signature) in tissue tumour 
collection B (table 6). The Cox proportional hazards 
model was then used to assess the eff ect on PFS and 
overall survival of demographic characteristics (age), 
clinical features (chemotherapy-treated or untreated, 
histotype, grade and substage) and the levels of miRNA 
expression in miR-200c, which was the only miRNA 
validated by qRT-PCR. miR-200c had a signifi cant eff ect 
on survival (table 7). In the univariate model, patients 
with high expression levels of miR-200c had a higher 
probability of overall survival and PFS than did patients 
with low expression levels (table 7). Kaplan-Meier 
survival estimates are shown in fi gure 4: patients with 
high expression levels of miR-200c had a better 
prognosis than did those with low levels, both in terms 
of overall survival and PFS. miR-200c was an 
independent prognostic factor in the multivariate model 
in terms of both overall survival and PFS (HR 0·094; 
95%CI 0·012–0·766, p=0·0272 for overall survival; and 
HR 0·035; 0·004–0·311, p=0·0026 for PFS; table 7). The 
likelihood ratio test assessed the fi t of the Cox 
proportional hazards model considering miR-200c in 
the analysis both of overall survival (LR 6·09, p=0·0136) 
and PFS (LR 12·61, p=0·0004); adding miR-200c to the 
multivariate model improved the C-statistic by 6·87% 
(from 0·78, 95% CI 0·62–0·95, to 0·84, 0·68–0·99) for 
overall survival, and by 10·03% (from 0·79, 0·64–0·94, 
to 0·87, 0·71–1·00) for PFS. These improvements were 
not statistically signifi cant.
Overall survival Progression-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p
miR-214 (high vs low) 2·973 (0·675–13·087) 0·1496 2·028 (0·352–11·684) 0·4287 3·410 (1·009–11·531) 0·0484 1·629 (0·449–5·915) 0·4579
miR-199a-3p (high vs low) 7·832 (1·033–59·382) 0·0464 10·356 (1·056–101·569) 0·0448 8·271 (1·939–35·273) 0·0043 6·427 (1·460–28·287) 0·0139
miR-199a-5p (high vs low) 8·689 (1·144–65·979) 0·0366 8·199 (0·880–76·415) 0·0647 11·798 (1·582–87·963) 0·0161 8·823 (1·136–68·559) 0·0374
miR-145 (high vs low) 0·288 (0·065–1·270) 0·1002 0·140 (0·026–0·752) 0·0219 4·947 (1·151–21·255) 0·0316 2·241 (0·474–10·589) 0·3085
miR-200b (high vs low) 2·137 (0·801–5·701) 0·1292 2·051 (0·640–6·570) 0·2264 3·197 (1·417–7·213) 0·0051 2·335 (0·857–6·363) 0·0974
miR-30 (high vs low) nd nd nd nd 0·322 (0·140–0·736) 0·0073 0·694 (0·239–2·015) 0·5022
miR-30a* (high vs low) 0·286 (0·081–1·004) 0·0506 0·500 (0·112–2·228) 0·3635 0·362 (0·160–0·817) 0·0144 0·931 (0·310–2·797) 0·8981
miR-30d (high vs low) 0·444 (0·165–1·195) 0·1080 0·640 (0·187–2·184) 0·4758 0·332 (0·142–0·779) 0·0113 0·595 (0·200–1·775) 0·3521
miR-200c (high vs low) 0·309 (0·112–0·850) 0·0230 0·244 (0·076–0·785) 0·0180 0·392 (0·174–0·885) 0·0241 0·419 (0·146–1·204) 0·1063
miR-20 (high vs low) 0·376 (0·141–1·006) 0·0513 0·367 (0·115–1·172) 0·0906 0·356 (0·159–0·801) 0·0125 0·392 (0·142–1·080) 0·0700
miR-143 (high vs low) 3·823 (1·089–13·425) 0·0364 2·811 (0·633–12·488) 0·1743 3·945 (1·455–10·701) 0·0070 2·234 (0·728–6·859) 0·1600
nd=not determined.
Table 5: Cox proportional hazards regression analysis of the relation between the S2 miRNAs and overall and progression-free survival for the 89 patients with stage I EOC from tumour 
tissue collection A
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To investigate events downstream of miR-200c 
downregulation in relapsing patients in more detail, we 
did in-silico screening to obtain a list of putative targets of 
miR-200c among diff erentially expressed genes that were 
detected in the same group of patients previously.4 Because 
the computational approaches currently used to predict 
miRNA–mRNA interactions have low precision and 
sensitivity, we compared in-silico predictions with high-
throughput measurements of gene expression.16 We 
focused on a subset of 188 genes identifi ed previously as 
being diff erentially expressed in relapsers versus non-
relapsers in the same cohort of patients.4 We used the 
TargetScan algorithm to search for genes with the right 
features to be putative downstream targets of miR-200c, 
and we identifi ed 11 genes that had at least one conserved 
response element in their 3  ´ untranslated regions 
Figure 3: Kaplan-Meier curves of independent prognostic factors for overall and progression-free survival for the S3 signature in tumour collection A
miRNAs expression levels were converted into discrete variables by dividing the samples into two classes (high and low), under or over the cutoff  points. Results of 
the log-rank test are shown.
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(webappendix p 5). We focused on VEGFA and tubulin III b 
isotype (TUBB3), the expression levels of which have been 
validated independently by qRT-PCR (webappendix p 6). 
In agreement with previous data on tumour tissue 
collection A,4 the expression of both VEGFA and TUBB3 
in relapsing patients is about double that in non-relapsers. 
Median expression levels for VEGFA were 0·0029 
and 0·0071 molecules of mRNA normalised for 
non-relapsers and relapsers, respectively (p=0·003, 
webappendix p 6); median expression levels for TUBB3 
Overall survival Progression free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
HR (95% CI) p HR (95% CI) p HR (95%CI) p HR (95%CI) p
Age (5-year increment) 1·281 (0·954–1·719) 0·0996 1·198 (0·828–1·733) 0·3370 1·179 (0·906–1·533) 0·2197 1·029 (0·755–1·403) 0·8541
Chemotherapy (yes vs no) 0·527 (0·159–1·746) 0·2948 0·539 (0·107–2·713) 0·4538 0·706 (0·225–2·209) 0·5491 1·197 (0·265–5·395) 0·8152
Histotype
Clear cell Reference Reference
Endometroid 0·663 (0·068–6·476) 0·7237 0·412 (0·037–4·590) 0·4710 0·674 (0·069–6·582) 0·7342 0·477 (0·043–5·306) 0·5466
Mucinous 1·185 (0·117–11·951) 0·8857 1·030 (0·081–13·028) 0·9817 1·209 (0·120–12·196) 0·8719 1·562 (0·135–18·100) 0·7211
Mullerian nd nd nd nd nd nd nd nd
Serous 2·406 (0·262–22·072) 0·4374 1·497 (0·138–16·192) 0·7399 2·793 (0·320–24·407) 0·3531 2·547 (0·254–25·524) 0·4265
Undiff erentiated nd nd nd nd nd nd nd nd
Figo I substage
A Reference Reference
B 0·427 (0·051–3·586) 0·4333 0·246 (0·017–3·552) 0·3032 0·361 (0·044–2·965) 0·3431 0·240 (0·021–2·763) 0·2524
C 0·689 (0·194–2·450) 0·5652 0·516 (0·073–3·667) 0·5082 0·550 (0·161–1·888) 0·3424 0·274 (0·045–1·656) 0·1582
Grade
1 Reference Reference
2 1·260 (0·221–7·186) 0·7950 4·177 (0·475–36·737) 0·1974 0·951 (0·179–5·048) 0·9527 1·931 (0·304–12·262) 0·4854
3 1·872 (0·490–7·152) 0·3593 10·650 (1·269–89·377) 0·0293 1·408 (0·399–4·969) 0·5950 5·041 (0·762–33·350) 0·0934
miR-200c (high vs low) 0·209 (0·045–0·970) 0·0456 0·094 (0·012–0·766) 0·0272 0·174 (0·038–0·793) 0·0239 0·035 (0·004–0·311) 0·0026
Cox proportional hazards regression analysis of overall survival and PFS for 55 patients with stage I EOC from tumour tissue collection B. nd=not determined.
Table 7: Univariate and multivariate analysis of tumour tissue collection B
Figure 4: Kaplan-Meier curves of independent prognostic factors for overall and progression-free survival for miR-200c in tumour collection B
miRNAs expression levels were converted into discrete variables by dividing the samples into two classes (high and low), under or over the cutoff  points. Results of 
the log-rank test are shown.
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PFS by miR-200c
9
2
26
29
10
2
26
29
Events Total Events Total
miR-200c Low
miR-200c High
χ2 (log-rank): 4·8636 (p=0·0274) χ2 (log-rank): 6·5414 (p=0·0105)
Non-relapsers (n=48) Relapsers (n=7) R p 
miR-199a-3p 212·1 (45·55–848·6) 543·9 (271–952·4) 2·56 0·33
miR-199a-5p 63·38 (28·31–211·9) 197·2 (59·47–239·3) 3·11 0·19
miR-200c 9·34 (4·17–18·56) 3·82 (3·38–5·93) 0·40 0·047
All data are median distribution (IQR) of fl uorescence intensity, normalised, unless otherwise stated. R=the ratio of the 
median distribution of relapsers compared with non-relapsers. p=the level of signifi cance according to the 
Mann-Whitney t test.
Table 6: RT-PCR expression analysis of the S3 signature
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were 0·0025 and 0·0068 for non-relapsers and relapsers, 
respectively (p=0·00097, webappendix p 6). Results 
relating to VEGFA were confi rmed when analysed by 
association with survival in both tissue collections A 
and B. In tissue collection A, univariate analysis suggested 
that patients with a high level of VEGFA expression had 
signifi cantly higher hazards ratios both for overall survival 
and progression-free survival (table 8); Kaplan-Meier 
analyses suggested that patients with low levels of 
expression of VEGFA had a better prognosis than those 
with higher levels, both in terms of overall survival and 
PFS (webappendix p 7), and multivariate analysis including 
demographic and clinical factors showed that VEGFA 
expression was independently associated with overall 
survival and progression-free survival (table 8). In tissue 
collection B, diff erences in VEGFA expression levels were 
confi rmed between relapsers and non-relapsers (median 
expression levels for VEGFA were 0·00018 and 0·0011 for 
non-relapsers and relapsers, respectively, p=0·0035; 
webappendix p 6). Univariate analysis and Kaplan-Meier 
analyses suggested that patients with higher expression 
levels of VEGFA had a worse prognosis in terms of PFS 
than those with lower levels (table 8; webappendix p 8). 
However, VEGFA expression was not a signifi cant 
prognostic factor in the multivariate analyses (table 8).
Discussion
This study suggests that the expression of miR-200c in 
patients with stage I EOC correlates with disease outcome. 
FIGO stage is used to defi ne the spread of the disease at 
diagnosis, and it is currently one of the most important 
prognostic factors for survival in EOC. Patients with stage I 
disease generally have good prognosis, whereas 
stages III–IV are associated with poor overall survival, and 
shorter PFS within 5 years of diagnosis. The risk of 
recurrence is higher in patients with certain clinical and 
histopathological features, such as grade 3, substage C, or 
clear-cell histotype. Adjuvant chemotherapy can prolong 
survival in these subgroups, although relapses in 
theoretically low-risk patients are common.1 The challenge 
at present is to identify new molecular features with 
prognostic signifi cance to distinguish which patients are at 
high risk and would benefi t most from additional medical 
intervention. A problem is that stage I EOC is not common: 
less than 10% of patients with EOC are diagnosed as stage I 
every year, which makes statistical and clinical interpretation 
diffi  cult. An additional level of complexity is generated by 
the controversial relationship between stages. Mirroring 
models from other solid tumours (eg, colon cancer), 
stage I EOC has long been considered an early phase in 
tumour progression. However, recent data on the possible 
pathogenesis of EOC strongly suggests that stage I disease, 
especially non-relapsing, might be a completely diff erent 
disease, not just an early step in the progression of EOC 
toward malignancy. However, this theory has not yet been 
generally accepted.17
This heterogeneous clinical and pathological scenario 
mirrors, at the molecular level, the complex genomic 
rearrangements and structural variations observed in the 
ovarian cancer genome, which has until now made it 
diffi  cult to exploit genome-wide information to stratify 
patients more precisely for diagnosis and prognosis. 
miRNAs now off er a new regulatory model of gene 
expression, and miRNA expression signatures correlate 
well with specifi c clinical characteristics of cancer, so that 
they can be used to classify normal and cancerous tissues, 
as well as for prognosis.18–20 Despite partial overlap 
between diff erent studies, data on EOC thus far indicates 
that the miRNA landscape is very important to understand 
ovarian cancer biology and therapy.21 miRNAs have been 
found to be downregulated in EOC cells compared with 
normal surface epithelial cells of the ovary.22 The clinical 
and pathological signifi cance has been documented, 
mainly in stage III–IV disease with sensitivity or resistance 
Overall survival Progression-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p
Tissue collection A
VEGFA (high vs low) 5·033 (1·827–13·865) 0·0018 5·560 (1·538–20·103) 0·0089 5·615 (1·668–18·902) 0·0053 5·843 (1·556–21·950) 0·0089
TUBB3 (high vs low) 1·998 (0·725–5·500) 0·1806 2·312 (0·722–7·402) 0·1582 2·081 (0·930–4·655) 0·0744 2·735 (1·039–7·198) 0·0416
Tissue collection B
VEGFA (high vs low) 3·683 (0·793–17·101) 0·0960 2·900 (0·554–15·180) 0·2074 4·590 (1·005–20·964) 0·0492 4·842 (0·941–24·913) 0·0591
Data for TUBB3 in tumour tissue collection B is not reported, because TUBB3 did not have a signifi cant association with overall and pregression-free survival in univariate analysis of tumor tissue collection A.
Table 8: Univariate and multivariate analysis of association between VEGFA and TUBB3 expression and survival in the two tissue collections
Panel: Research in context
Systematic review
A systematic review using search terms such as “stage I EOC AND miRNA” returned no 
results. To our knowledge, no data were available on miRNA expression profi le in stage I EOC
Interpretation
If our fi ndings are confi rmed,  miR-200c expression levels could be used to stratify patients 
with stage I ovarian cancer more accurately, which would enable the most appropriate 
therapies to be selected according to risk of relapse. Our fi ndings also provide the rationale 
to investigate new therapies in selected cohorts of patients with stage I ovarian cancer.
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to platinum-based chemotherapy. miRNA loci are targeted 
by genetic and epigenetic defects,23 and altered expression 
of proteins involved in miRNA maturation, such as 
DICER and DROSHA, are associated with most miRNAs 
alterations reported in stage III–IV disease.6
To the best of our knowledge, no data are available on 
miRNAs in stage I EOC, particularly in relation to 
prognosis. To identify miRNAs that are diff erentially 
expressed in relapsing and non-relapsing patients, our 
study made use of tumour samples from a cohort of 
144 patients (29 of whom relapsed) with stage I EOC, 
gathered from two independent tumour tissue collections. 
All samples were taken from patients who were naive to 
chemotherapy presurgery, and who had a minimum of 
5-years follow-up (median follow-up was 9 years). The 
patients from tumour tissue collection A had already been 
characterised by our group as lacking any mutation in the 
TP53 gene, and a gene-expression signature of 188 markers 
was associated with relapse.4 We found that the loss of 
miR-200c is a hallmark of poor prognosis in stage I EOC, 
and the loss of miR-200c parallels increased expression 
levels of VEGFA, which is a putative functional downstream 
miR-200c target that correlates with PFS and overall 
survival in multivariate analysis.
By contrast with stages III–IV EOC, the small proportion 
of patients who are diagnosed with stage I disease has 
made it diffi  cult to recruit cohorts of patients that are 
large enough to achieve suitable statistical power. In this 
context, the miRNAs that we found to be signifi cantly 
associated with overall survival and PFS might be an 
important part of a larger set of predictive factors. Further 
studies stemming from this fi rst attempt are likely to add 
to the list of miRNAs with prognostic value.
Our data suggest that a small subset of miRNAs 
correlate with prognosis, although marked diff erences in 
miRNA expression profi les were not noted. This 
conclusion is consistent with the idea that a small set of 
tumour features can cause diff erences in aggressiveness 
and outcome. The fact that gross miRNA alterations were 
not detected is in accordance with the fi nding that DICER 
and DROSHA levels were comparable in the relapsing 
and non-relapsing patients (webappendix p 6).
Of the 34 top-ranked diff erentially expressed miRNAs 
defi ned by the microarray analysis as a signature of relapse, 
we focused our attention on 21 miRNAs for which qRT-PCR 
amplifi cation parameters enabled us to draw conclusions. 
miR-200c was correlated independently with survival in 
the two independent datasets, and in line with previous 
data24 the miR-199 family was found upregulated in tumour 
tissue collection A. We cannot draw any conclusion at the 
moment about the remaining 13 miRNAs that have yet to 
be analysed; this point will be addressed in future studies.
miR-200c expression levels were independently 
associated with survival in the multivariate model. Thus, 
despite patients’ diff erent genetic backgrounds and 
histologically complex characteristics, miR-200c is linked 
to general mechanisms of relapse. The miR-200 family 
consists of fi ve members localised on two genomic clusters 
(miR-200a/b and miR-429 on chromosome 1, and miR-200c 
and miR-141 on chromosome 12).25 Interestingly, high 
levels of expression of all miR-200 family members have 
been linked with ovarian cancer in several studies.21,26 
Moreover, high expression levels of the miR-200 family are 
associated with shorter PFS and overall survival of patients 
with ovarian cancer.26 Although the expression levels of 
miR-200a and miR-200b might be lower in stage III than 
in stage I tumours,24 a high level of miR-200a expression in 
stage III ovarian cancer correlates with poor outcome.27
From a functional point of view, several targets for 
miR-200c have already been identifi ed. In many cancers, 
including EOC stages III/IV, miR-200c has been identifi ed 
as a marker of epithelial cells, and a powerful master 
regulator of epithelial-to-mesenchymal transition, through 
a negative-feedback loop with the transcription factors 
ZEB1 and TGFBR2. In our study, loss of miR-200c did not 
aff ect the expression of either of these (webappendix p 6), 
suggesting that this miRNA functions diff erently in stage I 
disease. Current bioinformatic methods to predict 
miRNAs targets have low sensitivity and precision, 
providing a large number of potential targets, many of 
which are probably false-positive.28 To narrow down the 
list of potential genes of interest, we used the intersection 
of miR-200c predicted targets with a list of genes previously 
identifi ed and diff erently expressed in relapsing patients.4 
Among the downstream targets of miR-200c, the VEGFA 
and TUBB3 genes were signifi cantly upregulated in 
patients who relapsed. High VEGFA mRNA expression 
levels were also associated in both univariate and 
multivariate analyses with reduced overall survival and 
PFS. Although we have not provided a mechanistic link 
between reduced miR-200c expression levels and increased 
VEGFA mRNA, our preliminary results are in line with 
recently published data.29 Liu and colleagues29 showed in 
two independent data sets of clear-cell renal-cell carcinoma, 
and in normal tissues, a strong anti-correlation between 
miR-200c expression levels and VEGFA mRNA levels. 
This point merits further study, particularly considering 
the potential relevance of this target for new therapeutic 
approaches in stage I EOC.
Although our fi ndings need to be validated in a larger 
cohort, this study shows in unprecedented resolution and 
detail the transcriptional regulation mechanisms that drive 
stage I EOC characteristics. Assessing miR-200c or VEGFA 
levels might serve to stratify patients for alternative 
treatments such as antibodies against VEGF, which has 
recently been shown to be useful in the treatment of 
advanced ovarian cancer.30 The other potential miR-200c 
target that was downregulated was TUBB3. This gene 
encodes class III b tubulin, which is a direct target of 
miR-200c, and the expression of which has been shown to 
be associated with aggressive and drug-resistant cancers.31 
In advanced stages of EOC, levels of TUBB3 expression 
correlate with poor outcome.32 Consistent with recent 
results that suggest an inverse relationship between 
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miR-200c and TUBB3 expression in advanced EOC,33 our 
study suggests that TUBB3 overexpression might be a 
negative prognostic marker in stage I EOC. Further studies 
using diff erent techniques (eg, in-situ hybridisation or 
RT-PCR coupled with laser capture microdissection) are 
clearly needed to establish whether miR-200c has the 
potential to be a prognostic biomarker in stage I EOC. As 
soon as the technology has been validated, it would be 
interesting to measure miR-200c levels in peripheral blood 
as a marker for screening and prognostic purposes.34 If our 
fi ndings can be confi rmed in other studies, miR-200c 
might serve as a molecular marker for the prediction of 
patient response to standard treatment (platinum-based or 
paclitaxel-based chemotherapy), which might reduce cost 
and minimise drug toxicity for those who do not benefi t 
from the treatment. Additionally, new investigational and 
anti-angiogenic agent combinations could be proposed 
earlier in the treatment algorithm for those patients.
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